EndrenyiL, InabaT, and KalowW. (1976). Genetic study of amobarbital elimination based on its kinetics in twins. Clin Pharmacol Ther, 20, 701–714.
2.
KalowW, OzdemirV, TangBK, TothfalusiL, and EndrenyiL. (1999). The science of pharmacological variability: An essay. Clin Pharmacol Ther, 66, 445–447.
3.
KalowW, TangBK, and EndrenyiL. (1998). Hypothesis: Comparisons of inter and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics, 8, 283–289.
4.
MatthaeiJ, BrockmöllerJ, TzvetkovMV, et al. (2015). Heritability of metoprolol and torsemide pharmacokinetics. Clin Pharmacol Ther, 98, 611–621.
5.
OzdemirV, KalowW, TangBK, PatersonAD, WalkerSE, EndrenyiL, and KashubaAD. (2000). Evaluation of the genetic component of variability in CYP3A4 activity: A repeated drug administration method. Pharmacogenetics, 10, 373–388.
6.
OzdemirV, KalowW, TothfalusiL, et al. (2005). Multigenic control of drug response and regulatory decision-making in pharmacogenomics: The need for an upper-bound estimate of genetic contributions. Curr Pharmacogenomics, 3, 53–71.
7.
VesellES. (1992). Pharmacogenetic perspectives gained from twin and family studies. In: Pharmacogenetics of Drug Metabolism. Kalow W, ed. New York: Pergamon Press, Inc., pp. 843–863.
